Results 71 to 80 of about 18,395 (294)

Herba Lysimachiae Polysaccharide‐Modified Selenium Nanoparticles Alleviate Oxidative Injury in Kidney Stones via TOMM22‐Regulated Mitophagy Activation

Advanced Science, EarlyView.
HLP‐SeNPs, a Lysimachia christinae polysaccharide‐modified selenium nanoparticle, treat kidney stones by downregulating TOMM22 expression, which reduces PINK1 translocation into mitochondria and promotes its retention on the outer mitochondrial membrane.
Junyi Yang, Guoruiyu Lyu, Wenlong Wan, Dongfeng Yuan, Jiabo Li, Yongqi Wang, Baokang Wang, Zhilong Ma, Yuanyuan Yang, Yang Xun, Xiao Yu   +10 more
wiley   +1 more source

Molecular classification of membranous nephropathy

, 2019
PURPOSE OF REVIEW: Continuous expansion of our knowledge in the pathogenesis of membranous nephropathy possible by the identification of antibodies recognized specific podocytes antigens results in unprecedent patient management strategy. RECENT FINDINGS:
Pozdzik, Agnieszka, Touzani, Fahd, Brochériou, Isabelle, Corazza, Francis   +3 more
core   +1 more source

The Spectrum of Biopsy‐Proven Renal Diseases in Chinese Elderly Patients and Its Temporal Shift Over 20 Years: A Retrospective Cohort Study

AGING MEDICINE, EarlyView.
This 20‐year retrospective study reveals a significant increase in renal biopsy utilization and a pivotal shift in biopsy‐proven renal disease among Chinese elderly patients. Secondary glomerular nephropathy (particularly diabetic nephropathy and hypertensive nephropathy) has surpassed primary glomerular nephropathy as the leading biopsy‐proven ...
Shasha Han, Lengnan Xu, Ying Sun, Fang Fang, Xin Liu   +4 more
wiley   +1 more source

Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy

BMC Nephrology, 2020
Background The kidney is a major target in primary antiphospholipid syndrome. Several types of nephropathy have been reported, the most frequent being acute or chronic specific vascular nephropathies and membranous nephropathy.
Maxime Teisseyre, Hélène Perrochia, Pascal Reboul, Sylvain Cariou, Sophie Renaud, Cédric Aglae, Olivier Moranne   +6 more
doaj   +1 more source

Membranous nephropathy in the UK Biobank

PLOS ONE, 2023
Background Despite MN being one of the most common causes of nephrotic syndrome worldwide, its biological and environmental determinants are poorly understood in large-part due to it being a rare disease. Making use of the UK Biobank, a unique resource holding a clinical dataset and stored DNA, serum and urine for ~500,000 participants, this study ...
Patrick Hamilton, Kieran Blaikie, Stephen A. Roberts, Matthew Gittins, Mallory L. Downie, Sanjana Gupta, Catalin Voinescu, Durga Kanigicherla, Horia Stanescu, Robert Kleta, Paul Brenchley   +10 more
openaire   +5 more sources

Xstainer: A Novel Virtual Staining Tool Powered by Advanced Deep Learning Techniques

Advanced Intelligent Systems, EarlyView.
Xstainer is a deep learning–based virtual staining framework that converts hematoxylin and eosin‐stained whole slide images into multiple histochemical stains, including Masson's trichrome, Periodic acid‐Schiff, Jones methenamine silver, and Toluidine blue.
Fatma Nur Kinali, Derya Demir, Kutsev B. Ozyoruk, Yasin Almalioglu, Emre C. Kose, Drew F. K. Williamson, Gurdeniz Serin, G. Evren Keles, Banu S. Kumbaraci, Ceren Utku, Uguray P. Hacisalihoglu, Ilknur Turkmen, Figen Ozturk, Kayhan Basak, Yavuz Nuri Ertas, Mehmet Turan   +15 more
wiley   +1 more source

Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy

Kidney International Reports
Introduction: Rituximab is a first-line treatment for primary membranous nephropathy (pMN), with proven efficacy and safety. The use of monoclonal antibodies such as rituximab can lead to the formation of antidrug antibodies that may interfere with the ...
Marco Allinovi, Maxime Teisseyre, Matteo Accinno, Cecilia Finocchi, Vincent L.M. Esnault, Marion Cremoni, Tommaso Mazzierli, Daniela Lazzarini, Micaela Anna Casiraghi, Céline Fernandez, Kévin Zorzi, Vesna Brglez, Lorenzo Cosmi, Andrea Matucci, Leonardo Caroti, Giulia Antognoli, Calogero Lino Cirami, Alessandra Vultaggio, Barbara Seitz-Polski   +18 more
doaj   +1 more source

Rituximab in Idiopathic Membranous Nephropathy [PDF]

Journal of the American Society of Nephrology, 2012
Selective depletion of B cells with the mAb rituximab may benefit the autoimmune glomerular disease idiopathic membranous nephropathy (IMN). Here, we describe our experience treating 100 consecutive IMN patients with persistent nephrotic syndrome with rituximab. We defined complete remission as persistent proteinuria
P. Ruggenenti, P. Cravedi, A. Chianca, A. Perna, B. Ruggiero, F. Gaspari, A. Rambaldi, M. Marasà, G. Remuzzi   +8 more
openaire   +3 more sources

Late‐Stage Functionalization of Peptides on the Solid Phase

Angewandte Chemie International Edition, EarlyView.
Peptide modifications are essential to control pharmacodynamic and pharmacokinetic properties of peptide drugs. Consequently, strategies that allow for efficient and rapid incorporation of non‐canonical modifications into peptides in parallel formats are highly sought after.
Marius Werner, Truc Lam Pham, Franziska Thomas   +2 more
wiley   +1 more source

Membranous nephropathy [PDF]

Current Opinion in Nephrology and Hypertension, 2012
Primary membranous nephropathy is a common glomerular disease characterized by sub-epithelial immune deposits that has become the prototype of an autoimmune glomerular disease. The purpose of this review is to highlight recent advances regarding the pathogenesis of membranous nephropathy as well as potential new therapies.The discovery of two major ...
Sandra M S, Herrmann, Sanjeev, Sethi, Fernando C, Fervenza   +2 more
openaire   +2 more sources